Rani Therapeutics Holdings RANI 深 滬
已收盤 12-19 16:00:00 美东时间
1.51
-0.010
-0.66%
華盛通- 最 高1.53
- 今 開1.51
- 成交量 479.03万股
- 最 低 1.45
- 昨 收 1.52
- 總市值 5069.12万
- 52周最高 3.87
- 市盈率 靜 --
- 換手率 14.27%
- 52周最低 0.387
- 委 比 -20.77%
- 總股本 3357.03万
- 歷史最高 36.27
- 量 比 1.52
- 振 幅 5.26%
- 歷史最低 0.387
- 每 手 1
- 風險率 0.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rani Therapeutics to Participate in the Evercore Healthcare Conference
Rani Therapeutics' management will participate in the 8thAnnual Evercore Healthcare Conference on December 3, 2025, in Coral Gables, FL. CEO Talat Imran and CFO Svai Sanford will engage in Fireside Chat and 1x1 meetings. Interested parties can access the live webcast via the company's Investor Relations website, with a replay available post-presentation. Rani Therapeutics specializes in oral delivery of biologics using its RaniPill® capsule techn...
11-24 21:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers enGene Holdings (NASDAQ:ENGN) stock moved upwards by 3.5% to $7.12 dur...
11-19 05:06
Rani Therapeutics Hldgs Q3 EPS $(0.12) Beats $(0.15) Estimate
Cash, cash equivalents and marketable securities as of September 30, 2025 totaled $4.1 million, compared to $27.6 million for the year ended December 31, 2024. Rani expects its cash, and cash equivalents, including the
11-07 05:57
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
Rani Therapeutics announced a $1.085 billion collaboration with Chugai Pharmaceutical to develop oral therapies using its RaniPill® platform. The company also completed a $60.3 million private placement led by Samsara BioCapital and appointed Abraham Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. With enhanced cash runway into 2028, Rani plans to initiate a Phase 1 clinical trial for its obesity treatment RT-114 by year-end.
11-06 21:30
期权扫描 | 挑战AI泡沫？英伟达、Palantir期权多空分歧巨大；AMD绩后大跌近5%，期权成交翻倍
“大空头”挑战AI泡沫，同时买入辉瑞、哈里伯顿看涨期权；英伟达、Palantir期权多空分歧巨大；AMD绩后大跌近5%，期权成交翻倍>>
11-05 17:05
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Cabaletta Bio (NASDAQ:CABA) shares rose 36.6% to $3.38 during Friday's...
11-01 01:06
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
SAN JOSE, Calif., Oct. 30, 2025 – Rani Therapeutics Holding, Inc. announced that it will present preclinical data on its RaniPill® capsule at ObesityWeek® 2025 on November 4-7, 2025, in Atlanta, Georgia. The presentation titled "Oral Semaglutide (RT-116) in Dogs is Bioequivalent to SC Injections and Elicits Similar Weight Loss" will be part of a poster session on November 6, 2025, from 2:30 pm – 3:30 pm E.T., featuring Rani's oral delivery platfo...
10-30 12:00
Epam, Westinghouse, Kala, Rani, Verisign: Major Stock Moves!
Insiders have been trading these 5 stocks: (($EPAM)), (($WAB)), (($KALA)), (($R...
10-25 21:01
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
Rani Therapeutics announced the appointment of Abraham Bassan and Vasudev Bailey, Ph.D., to its Board of Directors, while Andrew Farquharson and Maulik Nanavaty have stepped down. The company also closed a private placement raising approximately $60.3 million, led by Samsara BioCapital, with participation from Anomaly Ventures, RA Capital Management, and others. Rani focuses on oral delivery of biologics and drugs, developing the RaniPill® capsul...
10-23 20:05
美股牛股 | 散户追捧+业务规模扩大！BYND大涨146.3%；生物技术股RANI涨26.7%
散户追捧+业务规模扩大！BYND大涨146.3%，近三交易日涨约6倍；生物技术股RANI涨26.7%，与中外制药达成重大合作协议>>
10-22 14:01
